ClinicalTrials.gg
SuspendedNCT04912115Updated Nov 18, 2023

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

A Phase 2 interventional study of Ketamine and Midazolam in Dyskinesias, Movement Disorders and Central Nervous System Diseases, sponsored by PharmaTher Inc.. Suspended at 7 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by PharmaTher Inc. · Phase 2, Interventional, and Treatment

Why this study was suspended
Seeking Pivotal study initiation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Dyskinesias with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyskinesias · United States.

Enrollment
51st of 82
30 · median 41
Started
2021
with 3 others
Phase 2
32 of 101
1 open now
Registered
85th of 101
by date

Among the 101 studies in Dyskinesias with a site in United States, this one is the 51st largest by enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2021, is one of 32 in phase 2, and was the 85th registered.

Dyskinesias

179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.

Browse Dyskinesias studies →

Open to participants now

8 of the 101 studies in Dyskinesias with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Dyskinesias studies recruiting now, 4 (25%) set no upper age limit and 8 (50%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Dyskinesias with a site in United States, or all of them as a file.
02

Study summary

A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.

Read the detailed description

This Phase II trial is a prospective, double-blind, randomized, parallel trial-design with two arms. Subjects will be randomized to treatment with the investigational product (ketamine) or an active control (midazolam). The active control causes mild sedation and is employed to minimize unmasking of the test article.

The study is an out-patient study. However, infusion days and days involving prolonged assessments are expected to require the subject to be onsite. Subjects will return to the site for safety and efficacy evaluations. On Day 1, PK samples will be collected near the end of Infusion 1 and post-infusion to evaluate near-steady-state blood levels in all subjects. Intensive PK sampling will be conducted in all subjects prior to, during, and a few hours after Infusion 2 (Day 5 ± 2).

The primary objective of the study is to evaluate the effects of low-dose intravenous infusion of ketamine on levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. All patients included in the study should meet the inclusion criteria. Half of the participants will receive ketamine, while the other half will receive active placebo (Midazolam). All participants will be assigned to either the active group or the control group randomly. During the clinical trial, both investigators and patients are double-blind except serious adverse events occurred.

03

Conditions studied

  • Dyskinesias
  • Movement Disorders
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurologic Manifestations
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with Parkinson's Disease as defined by the UK Parkinson's Disease Society Brain Bank Criteria
  2. Signed a current IEC approved form
  3. Male or female patients between ages 30-85 years
  4. At least three years of prior treatment with levodopa of at least 400 mg daily subject to a maximum of 8 divided doses per day (excluding bedtime and nighttime)
  5. Waking day dyskinesia of > 25% determined as a score of ≥2 as per Question 4.1 on the UPDRS
  6. Ambulatory or ambulatory-aided (e.g., walker or cane) and able to complete study assessments
  7. Have been on stable doses of all anti-Parkinson's medications for 30 days prior to entry into the study, including a levodopa preparation administered not less than three times daily, and be willing to remain on the same doses of medications throughout the course of the study
  8. Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and the patient must be willing to continue the same doses and regimens during study participation.
  9. The subject/caregiver must demonstrate the ability to complete an accurate home diary based on training and evaluation (visit 2)
  10. Subjects must have available a responsible adult caregiver/companion who will drive the subject home following infusions
  11. Female subjects not of
  12. Male subjects, regardless of their fertility status, with nonpregnant women of childbearing potential (WOCBP) partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use a highly effective (less than 1% failure rate) method of (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) or effective method of contraception (such as diaphragms with spermicide or cervical sponges) for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of an atypical or secondary Parkinsonian syndrome
  2. Lack of documented response to levodopa
  3. Hoehn and Yahr stage of 5
  4. Known prior exposure to ketamine or other NMDA inhibitors within the last 30 days
  5. History of neurosurgical intervention related to PD (e.g., deep brain stimulation)
  6. History of seizures within two years prior to screening
  7. History of or stroke within two years prior to screening
  8. History of intracerebral hemorrhage due to hypertension.
  9. History of arrhythmia or unstable angina within the past five years
  10. History of myocardial infarction within 2 years prior to screening
  11. History of Class 3 or 4 heart failure within 2 years prior to screening
  12. Aneurysmal vascular disease (e.g., intracranial, thoracic or abdominal aorta)
  13. History of hypertensive encephalopathy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Ketamine

    Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.1 mg/kg/hr to 0.30 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).

    Drug: Ketamine

  • Active comparator
    Midazolam

    Midazolam will be administered as intravenous infusions with infusion rates ranging from 0.009 mg/kg/hr to 0.027 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).

    Drug: Midazolam

Interventions

  • Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).

  • Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.

06

What researchers measure

Primary outcomes

  1. Change in the Unified Dyskinesia Rating Scale (UDysRS) total score from Baseline to Week 8.

    The change from baseline to week 8 of treatment in the sum of the items comprising the Unified Dyskinesia Rating Scale (UDysRS). The Unified Dyskinesia Rating Scale (UDysRS) is administered to assess dyskinesia. The scoring range is 0-104, where higher score means more dyskinesia.

    Time frame: 8 weeks

Secondary outcomes

  1. Change in total daily OFF times as assessed by subject completed 24-hour diaries, from Baseline to Week 8.

    Change in daily "OFF"-time as assessed with patient diaries from run-in to week 8. This is a self administered diary where patients assess their motor state every half hour during 24 hours.

    Time frame: 8 weeks

  2. Change in the UPDRS total score of part III (motor) and sum score of Questions 4.1 and 4.2 (dyskinesia) in part IV from Baseline to Week 8.

    Change in MDS-UPDRS sum score of part III (Motor Examination) from baseline to week 8. Minimum value is 0 and maximum value is 124. Higher score mean a worse outcome.

    Time frame: 8 weeks

07

Study locations

7 sites
  • Investigative Site #7
    Tucson, Arizona 85719, United States
  • Investigative Site #2
    Chula Vista, California 91910, United States
  • Investigative Site #1
    Fountain Valley, California 92708, United States
  • Investigative Site #3
    Miami, Florida 33032, United States
  • Investigative Site #6
    Miami, Florida 33175, United States
  • Investigative Site #5
    Rolling Meadows, Illinois 60008, United States
  • Investigative Site #4
    Plymouth, Michigan 48170, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2023, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
Jun 3, 2021
StartActual
Oct 5, 2021
Primary completionEst.
Dec 30, 2023
CompletionEst.
Mar 30, 2024
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04912115
Lead sponsor
PharmaTher Inc.
Responsible party
Sponsor
First posted
Jun 3, 2021
Start date
Oct 5, 2021
Primary completion
Dec 30, 2023 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
Nov 18, 2023

Study contacts

Study Director
study director · PharmaTher Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion